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Abstract
Background: p16 expression is a well established biomarker of cervical dysplasia and carcinoma arising from high
risk human papilloma virus infection. Increased p16 expression is also seen in squamous neoplasms arising at other
sites, including head, neck, and oropharyngeal tract. Squamous lesions are also frequently encountered at ocular
surface and peri-orbital skin sites, but the prevalence of increased p16 expression in these lesions has been poorly
studied.
Methods: We retrospectively surveyed 13 ocular surface and 16 orbital squamous lesions biopsied at UC San Diego
Healthcare System and VA San Diego Healthcare System for p16 expression by immunohistochemistry. These cases
included ocular surface lesions with diagnoses of conjunctival intraepithelial neoplasm (CIN) and squamous cell
carcinoma in situ. Peri-orbital eyelid biopsies included lesions with diagnoses of SCCis and invasive squamous cell
carcinoma. We performed multivariate logistic regression, followed by student’s T-test or Fisher's exact test to
determine if there were statistically significant associations between p16 immunoreactivity and patient age, gender,
diagnosis, and ethnicity. Statistical significance was defined as p < 0.05.
Results: We found an unexpectedly large prevalence of strong nuclear and cytoplasmic p16 immunoreactivity in
our cases. Almost all of the ocular surface squamous lesions were diffusely positive for p16 expression (12/13). All of
the periorbital lesions showed diffuse p16 immunoreactivity (16/16). Altogether, 28/29 lesions tested showed strong
and diffuse p16 expression. We found no statistically significant correlation between p16 expression and patient
age, gender, ethnicity, or diagnosis. In 6 of the peri-orbital biopsies, we had sufficient tissue to assess high-risk HPV
expression by in situ hybridization. Interestingly, all of these cases were negative for HPV, despite strong p16
expression.
Conclusion: Strong p16 expression was observed in virtually all of the ocular surface and peri-orbital squamous
neoplasms in our study. The relationship between p16 expression and HPV infection in ocular surface and peri-orbital
sites requires further investigation.
Background
HPV is linked to development of cervical, anogenital,
head/neck, and lung squamous lesions and carcinomas
[1–5]. Increased p16INK4A expression is seen in HPV-
associated squamous lesions, and the strength and sub-
cellular staining pattern of p16 immunohistochemical
reactivity correlates closely with the degree of dysplasia,
with higher-grade lesions showing intense, diffusely posi-
tive nuclear and cytoplasmic p16 expression in affected
squamous cells [6–14]. Increased p16INK4A expression
arises from neutralization of cellular p53 and pRb tumor
suppressor proteins by HPV E6 and E7 oncogenes in
infected cells [15, 16]. Low-risk HPV subtypes typically
show less p16INK4A induction because they produce E6
and E7 viral oncogenes with lower ability to neutralize
endogenous tumor suppressors [17]. Therefore, p16INK4A
expression is commonly employed as a surrogate marker
of infection by high-risk HPV subtypes.
Malignant squamous lesions of ocular and peri-ocular
structures include conjunctival intraepithelial neoplasia
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(CIN) to frank invasive squamous cell carcinoma (SCC).
HPV has also been detected in prior studies of ocular and
peri-ocular squamous lesions and suggested to contribute
to the pathogenesis of squamous lesions in the eye [18–21].
However, very few studies have examined p16 expression in
squamous lesions resected from the eye, and there have
been conflicting findings from these reports. In a cohort of
HIV seropositive patients in Africa, Mwololo and col-
leagues findings found strong p16 immunoreactivity in
67 % (39 of 58) of SCC conjunctival biopsies [22]. However,
in a study of ocular surface and conjunctival squamous
lesions performed in Australia, Woods and colleagues
found p16 immunoreactivity in only 6.5 % (3 of 46) ocu-
lar surface squamous neoplasia biopsies and 12.5 % (3 of
24) conjunctival SCCs [23]. Interestingly, p16 immuno-
reactivity completely correlated with HPV detection by
PCR in this study [23].
In our study, we hypothesized that p16 immunoreactivity
was significantly increased in malignant ocular squamous
lesions. To examine this, we examined 29 ocular surface
and periorbital squamous lesions excised at our institution
that comprised malignant (CIN and SCC) ocular squamous
neoplasms. We performed p16 IHC analysis on all lesions,
followed by HPV ISH on a subset of p16-positive cases. We
compared the histopathologic and molecular findings with
clinical data to identify potential significant correlations be-
tween p16 expression in ocular squamous lesions and clin-
ical characteristics of our patient population.
Methods
Tissue specimens
We examined a total of 29 ocular surface and periorbital
eyelid squamous lesion cases retrieved from the VA San
Diego and UCSD Medical Center between July 2010-
May 2014. These cases were routinely fixed in 10 % for-
malin and embedded in paraffin. H&E (hematoxylin and
eosin)-stained slides were reviewed and classified by an
ophthalmologic pathologist. All lesions with a diagnosis of
CIN or SCC (in situ or invasive) were included in this
study. The study was approved by the Institutional Review
Boards at UCSD and VA San Diego.
p16 immunohistochemistry
Immunohistochemical studies for p16 were performed
using a Ventana Benchmark Ultra. The p16 antibody used
was a monoclonal mouse antibody (clone JC8, Santa Cruz
Biotechnology; dilution 1:80). Lesions were considered
positive for p16 when both cytoplasmic and nuclear stain-
ing was observed in epithelial cells. Staining in dendritic
cells and non-epithelial cells was disregarded.
HPV in-situ hybridization
In-situ hybridization was performed on formalin-fixed,
paraffin-embedded tissue by ARUP laboratories (Salt
Lake City, Utah). The test was run on a Ventana Bentana
Benchmark Ultra (Ventana Medical Systems, Inc), using
the INFORM HPV II FAMILY 6 (ASR) probe. A probe
set for high-risk HPV [16, 18] were employed (catalog
#2002899). This test is CLIA-certified for clinical use
and widely performed for evaluation of high risk HPVs
in suspicious tissue biopsies.
Statistical analysis
Statistical analysis was performed on CINs and SCCs.
The correlation between p16 immunoreactivity and pa-
tient’s age, gender, diagnosis, and ethnicity was first ana-
lyzed by Multivariate Logistic Regression using SAS 9.3,
followed by individual student’s T-test (for age difference)
or Fisher’s exact test (for gender, ethnicity, or diagnosis
differences). A difference was considered statistical signifi-
cant if p < 0.05.
Results
p16 expression by immunohistochemistry
A total of 29 cases were evaluated for p16 immunoreac-
tivity (Table 1). Patients ranged in age from 37 to 88 and
included 11 women and 18 men with White ethnicity
(by self-report) being the most common. The majority
of patients were seronegative for HIV (27/29). Negative
p16 immunoreactivity was defined as lacking cytoplas-
mic and nuclear labeling of the squamous keratino-
cytes (Fig. 1), while p16 was considered positive when
there was both strong cytoplasmic and nuclear label-
ing of dysplastic keratinocytes in the lesion. By this
criteria, 28 of the 29 cases showed strong p16 immu-
noreactivity of dysplastic squamous cells (Figs. 2, 3,
and 4 and Table 1). When grouped by diagnosis, all
of the SCCs (20/20) were p16-positive (Figs. 2 and 4,
Table 1), and 8/9 CINs were p16-positive (Table 1).
HPV detection by in-situ hybridization
HPV in-situ hybridization against HPV genotypes 6, 11,
16, and 18 was performed on 6 lesions in total that were
intensely and diffusely positive for p16 by immunohisto-
chemistry. Of six squamous cell carcinomas tested, none
were positive for HPV. CIN cases had insufficient
remaining tissue in the blocks to perform the HPV ISH
assay due to the small size of the conjunctival biopsy.
Clinical and statistical correlation
We next examined if positive p16 expression correlated
with pathologic type of squamous lesion, patient age
(less than or older than 50), patient gender, and ethnicity
(White, Hispanic) by multivariate logistic regression,
Student’s t-test, and Fischer’s exact test. No significant
differences were seen between the pathologic types of
lesions tested and p16 positivity (p >0.05). In addition,
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there were no significant differences between p16 posi-
tivity and age, gender, ethnicity or diagnosis.
Discussion
Our study reveals a surprisingly high prevalence of p16
immunoreactivity in ocular squamous lesions from our
patient population, but interestingly, these squamous
lesions with strong p16 expression did not show HPV 6,
11, 16, and 18 genetic material by ISH. We discuss some
potential causes for the increased p16 expression but
low HPV infection observed in our study.
P16 immunoreactivity is well established as a bio-
marker for HPV infection in sites such as cervix, and the
vast majority of HPV-associated cancers show increased
p16 expression [12–14, 24, 25]. However, p16 induction
has also been observed after inflammatory conditions,
after total body irradiation, and with prolonged genomic
damage, independent of HPV infection [26, 27] and in a
recent study of bladder SCC, about 1/3 of SCC cases
showed p16 immunoreactivity but no HPV genetic
material by in situ hybridization [28]. Similarly, in-
creased p16 expression did not correlate with HPV
infection in SCC from lung, skin and esophagus [29]. In
our ocular squamous neoplasms, it is possible that
increased p16 expression could arise from stresses other
than HPV infection, and indeed, solar damage was previ-
ously proposed as a risk factor for increased HPV infec-
tion in eye disease [19].
Our HPV ISH test was performed by ARUP labs, using
a commercially available limited HPV ISH probe against
Table 1 Patient clinico-pathologic profiles
Age Sex Anatomic site Ethnicity HIV status Pathologic diagnosis P16 immunoreactivity P16 IHC staining pattern ISH
71 M Eyelid Unknown Negative Invasive SCC Positive Nuc and cyto a
85 M Eyelid White Negative Invasive SCC Positive Nuc and cyto a
59 M Eyelid White Negative SCC in situ Positive Nuc and cyto a
46 M Conjunctiva White Negative invasive SCC Positive Nuc and cyto a
78 F Eyelid White Negative SCC in situ Positive Nuc and cyto a
37 M Conjunctiva Hispanic Negative SCC in situ Positive Nuc and cyto Negative
88 F Eyelid White Negative SCC in situ Positive Diffuse nuc and cyto Negative
89 F Eyelid White Negative SCC in situ Positive Diffuse nuc and cyto a
67 F Eyelid White Negative Invasive SCC Positive Diffuse nuc and cyto a
77 M Conjunctiva White Positive CIN Positive Diffuse nuc and cyto a
76 F Eyelid White Negative SCC in situ Positive Diffuse nuc and cyto Negative
47 M Cornea White Negative SCC in situ Positive Diffuse nuc and cyto a
45 F Eyelid White Negative Invasive SCC Positive Diffuse nuc and cyto Negative
76 F Eyelid White Negative SCC in situ Positive Scattered nuc and cyto a
61 M Eyelid White Negative Invasive SCC Positive Focal nuc and cyto Negative
88 F Eyelid White Negative Invasive SCC Positive Diffuse nuc and cyto Negative
88 F Eyelid White Negative SCC in situ Positive Patchy nuc and cyto a
88 F Eyelid White Negative SCC in situ Positive Focal nuc and cyto a
45 M Eyelid White Negative SCC in situ Positive Diffuse nuc and cyto a
65 M Eyelid Unknown Negative SCC in situ Positive Diffuse nuc and cyto a
76 M Conjunctiva Hispanic Negative CIN Positive Focal nuc and cyto a
32 F Conjunctiva White Negative CIN Positive Scattered nuc and cyto a
56 M Conjunctiva Hispanic Positive CIN Positive Scattered nuc and cyto a
46 M Cornea White Negative CIN Positive Diffuse nuc and cyto a
64 M Cornea/conjunctiva Unknown Negative SCC in situ Positive Diffuse nuc and cyto a
72 M Conjunctiva White Negative CIN Positive Diffuse nuc and cyto a
56 M Conjunctiva White Negative CIN Positive Scattered nuc and cyto a
40 M Conjunctiva Hispanic Positive CIN Negative N/A a
70 M Conjunctiva White Negative CIN Positive Diffuse nuc and cyto a
Nuc Nuclear, Cyto cytoplasmic
aNot performed
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Fig. 1 a Histology of the negative control, taken from a pterygia (20x, magnification). c Immunohistochemical staining for p16 in the same case
(20x magnification). Note the lack of staining in epithelial cells. b, d Positive control p16 immunohistochemical staining, taken from a squamous
cell carcinoma in-situ from cervix (4x and 20x, respectively). Note both cytoplasmic and nuclear reactivity
Fig. 2 a, b Histology of a squamous cell carcinoma in situ from eyelid biopsy (4x and 20x, respectively). c, d Immunohistochemical staining for
p16 in the same case (4x and 20x, respectively). Note the extensive cytoplasmic and nuclear reactivity
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Fig. 3 a, b Histology of an in-situ squamous cell carcinoma of the conjunctiva from a patient with HIV (4x and 20x, respectively).
c, d Immunohistochemical staining for p16 in the same case (4x and 20x, respectively). Note the lack of p16 staining in adjacent normal conjunctiva
with goblet cells. Arrows mark the transition between normal and dysplastic epithelium. e, f Immunohistochemical staining for Ki-67
(MIB-1). Note full-thickness reactivity in dysplastic epithelium
Fig. 4 a, b Histology of an invasive squamous cell carcinoma (4x and 20x, respectively). c, d Immunohistochemical staining for p16 in the same
case (4x and 20x, respectively). Note both cytoplasmic and nuclear reactivity
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HPV genotypes 6, 11, 16, and 18 that is widely used to
identify HPV infection in human tissue specimens. These
HPV genotypes are widely observed in cervical squamous
lesions but their trophism to other squamous sites is less
clear. Ateenyi-Agaba and colleagues isolated several
uncharacterized HPV genotypes from their conjunctival
SCC lesions [21]. It remains possible that in our speci-
mens, other HPV genotypes could be present and account
for the increased p16 expression. A broader spectrum
probe for more HPV genotypes could help reconcile p16
positive lesions that were initially negative [29].
HPV detection techniques vary in their sensitivity [30].
Our study employed a CLIA-approved ISH assay com-
monly used for cervical biopsies at our institution as a
confirmatory test for HPV in p16 positive ocular squa-
mous lesions. RT-PCR testing is more sensitive for HPV
testing [31, 32], and, in one study of oropharyngeal
SCCs, many ISH negative SCCs of the oropharynx were
positive by PCR [33]. Repeat HPV testing by different
methodologies may be required to identify HPV in cases
with high clinical suspicion. Further follow-up studies
using more sensitive and broader methodologies may be
helpful to determine if p16 expression in ocular squa-
mous lesions corresponds to HPV infection.
Conclusion
Our studies showed that p16 expression is frequently
increased in malignant squamous lesions arising at the
conjunctiva or adjoining eyelid.
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